Rita E. Numerof, PhD

The biopharmaceutical industry contemplates product innovation within the changing landscape of healthcare.

Rather than seeking a single indication for one large group, the orphan-drug approach segments the market for a drug more minutely.

The industry must be prepared for the impact of the sweeping changes expected from the new legislation.